Glaukos Co. (NYSE:GKOS) Director Aimee S. Weisner Sells 25,000 Shares

Glaukos Co. (NYSE:GKOS) Director Aimee S. Weisner sold 25,000 shares of the stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $120.00, for a total value of $3,000,000.00. Following the completion of the sale, the director now owns 30,119 shares of the company’s stock, valued at $3,614,280. The sale was disclosed in a filing with the SEC, which is available at this link.

Glaukos Stock Performance

Shares of GKOS stock traded down $0.14 on Monday, hitting $121.48. 329,149 shares of the stock traded hands, compared to its average volume of 600,086. The company has a market capitalization of $6.12 billion, a PE ratio of -42.35 and a beta of 1.05. The company’s fifty day moving average is $117.55 and its 200 day moving average is $104.02. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.48 and a quick ratio of 4.68. Glaukos Co. has a 1-year low of $59.22 and a 1-year high of $126.96.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.52). Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The company had revenue of $95.70 million for the quarter, compared to the consensus estimate of $88.86 million. During the same period last year, the firm posted ($0.55) EPS. The company’s revenue for the quarter was up 19.0% on a year-over-year basis. On average, equities research analysts predict that Glaukos Co. will post -2.25 earnings per share for the current fiscal year.

Institutional Trading of Glaukos

Several hedge funds have recently made changes to their positions in GKOS. National Bank of Canada FI acquired a new stake in shares of Glaukos in the 4th quarter worth about $46,000. GAMMA Investing LLC acquired a new stake in Glaukos in the 4th quarter valued at approximately $55,000. Quadrant Capital Group LLC raised its stake in Glaukos by 54.8% during the 4th quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock valued at $74,000 after acquiring an additional 329 shares in the last quarter. Caldwell Sutter Capital Inc. raised its stake in Glaukos by 5,860.0% during the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock valued at $140,000 after acquiring an additional 1,465 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC acquired a new position in Glaukos during the 2nd quarter worth $187,000. Institutional investors own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on GKOS shares. Piper Sandler increased their target price on Glaukos from $110.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. JPMorgan Chase & Co. lifted their price objective on shares of Glaukos from $108.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, May 2nd. Jefferies Financial Group upgraded shares of Glaukos from a “hold” rating to a “buy” rating and upped their target price for the company from $84.00 to $125.00 in a research note on Monday, May 6th. Truist Financial reaffirmed a “buy” rating and set a $145.00 price target (up previously from $141.00) on shares of Glaukos in a research note on Thursday, August 1st. Finally, BTIG Research upped their price objective on shares of Glaukos from $112.00 to $131.00 and gave the company a “buy” rating in a research report on Monday, July 15th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $127.73.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.